Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Rajman

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilolHsiu-Ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, et al.
European Journal of Clinical Pharmacology|May 28, 2016
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitorSurya P Ayalasomayajula, Thomas H Langenickel, Pierre Jordaan, et al.
Journal of Clinical Pharmacology|April 23, 2004
Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trialsSteven G Terra, Robert A Blum, Greg C Wei, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 11, 2016
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
Surya Ayalasomayajula, Thomas H Langenickel, Priya Chandra, et al.
British Journal of Clinical Pharmacology|December 15, 2015
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsThomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 2, 2016
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male SubjectsSurya Ayalasomayajula, Wei Pan, Yi Han, et al.
Clinical Neuropharmacology|June 21, 2005
Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson diseaseClaire Thalamas, Iris Rajman, Jaime Kulisevsky, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 25, 2017
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
Kenneth M Kulmatycki, Thomas Langenickel, Wai Hong Ng, et al.
British Journal of Clinical Pharmacology|December 17, 2014
Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group studyZhanna Kobalava, Svetlana Villevalde, Yulia Kotovskaya, et al.
Cardiovascular Therapeutics|March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionZhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilolHsiu-Ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, et al.
European Journal of Clinical Pharmacology|May 28, 2016
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitorSurya P Ayalasomayajula, Thomas H Langenickel, Pierre Jordaan, et al.
Journal of Clinical Pharmacology|April 23, 2004
Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trialsSteven G Terra, Robert A Blum, Greg C Wei, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 11, 2016
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
Surya Ayalasomayajula, Thomas H Langenickel, Priya Chandra, et al.
British Journal of Clinical Pharmacology|December 15, 2015
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsThomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 2, 2016
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male SubjectsSurya Ayalasomayajula, Wei Pan, Yi Han, et al.
Clinical Neuropharmacology|June 21, 2005
Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson diseaseClaire Thalamas, Iris Rajman, Jaime Kulisevsky, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 25, 2017
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
Kenneth M Kulmatycki, Thomas Langenickel, Wai Hong Ng, et al.
British Journal of Clinical Pharmacology|December 17, 2014
Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group studyZhanna Kobalava, Svetlana Villevalde, Yulia Kotovskaya, et al.
Cardiovascular Therapeutics|March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionZhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
Pageof 3